Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice.

PATRICIA PENSEL; GABRIELA ULLIO GAMBOA; JULIA FABRI; LAURA CEBALLOS; SERGIO SÁNCHEZ BRUNI; LUIS ALVAREZ; DANIEL ALLEMANDI; JEAN PIERRE BENOIT; SANTIAGO PALMA; MARÍA CELINA ELISSONDO

ELSEVIER SCIENCE BV

Lugar: Amsterdam; Año: 2015 p. 185 - 185

herapeutic failures attributed to medical management of cystic echinococcosis (CE) with albendazole(ABZ) have been primarily linked to the poor drug absorption rate resulting in low drug level in plasma andhydatid cysts. Lipid nanocapsules (LNCs) represent nanocarriers designed to encapsulate lipophilic drugs,such as ABZ. The goals of the current work were: (i) to characterize the plasma and cyst drug exposure afterthe administration of ABZ as ABZ-LNCs or ABZ suspension (ABZ-SUSP) in mice infected with Echinococcusgranulosus, and ii) to compare the clinical efficacies of both ABZ formulations. Enhanced ABZ sulphox-ide (ABZ-SO) concentration profiles were obtained in plasma and cysts from ABZ-LNC treated animals.ABZSO exposure (AUC0?LOQ) was significantly higher in plasma and cyst after the ABZ-LNC treatments,both orally and subcutaneously, compared to that observed after oral administration of ABZ-SUSP. Addi-tionally, ABZSO concentrations measured in cysts from ABZ-LNC treated mice we